Committed to the future
Our technology-driven drug discovery delivers breakthroughs
We work in an unbroken chain — from research and discovery, through development and commercialization — to surmount the challenges of innovating in new frontiers.
Breakthrough history
Our commitment to delivering breakthroughs has produced an exciting portfolio of medicines that have the potential to change treatment paradigms and understanding of diseases. Recent drug approvals add a new chapter to Kyowa Kirin’s rich history of innovation. We are excited to bring these medicines to patients and physicians across the United States.
Over the years, our portfolio has drawn from expertise in antibody engineering, fermentation technology, and manufacturing to create novel treatments. Our perspective is unique – it is not confined to one area of medicine but is built from knowledge in different disease areas and modalities. See more about our history here.
Immunology
Our expertise in antibody discovery and development has fueled new patents, development programs, and the creation of effective medicines for patients. It also has been at the forefront of key industry advancements, including the ability to safely and reliably reproduce fully human monoclonal antibodies that precisely eliminate target cells that cause disease. Learn more here.
Technology-driven drug discovery
We find inspiration for new drug discoveries in all stages of research, development, and commercialization. Around the world, we focus on 4 different modalities with applications in our therapeutic areas of focus: therapeutic antibodies, new small-molecule drugs, nucleic-acid drugs, and regenerative medicine. In La Jolla, our lab has deep expertise and a proud legacy of discovering therapeutic antibodies for further development. The team is also working to pioneer an Open Innovation model that will help vet the potential of more discoveries.
Nephrology
Oncology
Central nervous system (CNS)
Immunology & Allergy
